Sun Life Financial (NYSE:SLF) Q4 2025 Earnings call February 12, 2026 11:00 AM ET Company ParticipantsDavid Garg - EVP, Head of U.S. BusinessKevin Strain - CEOManjit Singh - President, AsiaNatalie Brady - SVP, Capital Management and Investor RelationsSteve Peacher - CEOTed Maloney - CEOTim Deacon - EVP and CFOTom Murphy - Head of Asset ManagementConference Call ParticipantsAlex Scott - AnalystDarko Mihelic - AnalystDoug Young - AnalystGabriel Dechaine - AnalystJohn Aiken - AnalystMario Mendonca - AnalystMik ...

Summary of Cullinan Therapeutics 2026 Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Focus**: Development of T cell engager programs for autoimmune diseases and oncology Key Priorities and Portfolio - **2026 Significance**: First year with catalysts across the entire portfolio, particularly for two high-priority T cell engager programs: - **CLN-978**: CD19 x CD3 bispecific T cell engager for autoimmune diseases - **CLN-049**: FLT3 x CD3 T cell engager for acute myeloid leukemia (AML) [5][6] CLN-978 Program - **Potential**: Considered a best-in-class molecule for autoimmune diseases with a global development program targeting lupus, rheumatoid arthritis (RA), and Sjögren's disease [6] - **Differentiation**: High binding affinity for CD19, small molecular size for better tissue penetration, and subcutaneous administration convenience [6] - **Data Readouts**: Planned throughout 2026 for all three indications [6] - **Market Interest**: B cell depletion remains a hot area, with strategic acquisitions in the sector, indicating strong market interest [7] CLN-049 Program - **Potential**: First-in-class potential for a broad group of AML patients, with compelling monotherapy efficacy data presented at ASH [8] - **Regulatory Designation**: Received Fast Track designation from the FDA, facilitating a pivotal single-arm study for potential approval [8] - **Commercial Opportunity**: Aiming for significant commercial potential in the AML market, with plans for a combination study later in the year [8][34] Financial Position - **Cash Reserves**: Over $430 million reported at the end of 2025, providing a runway into 2029 to advance programs without immediate capital raising needs [9] Clinical Development Updates - **Enrollment Progress**: Completed first two dose cohorts for CLN-978 and currently accruing into the 30 microgram dose level for lupus and RA studies [11] - **Efficacy Expectations**: Anticipating a dose-response effect for B cell depletion in upcoming data releases [14][15] Competitive Landscape - **Market Position**: The company aims to be the first to present company-sponsored data for a CD19 T-cell engager, enhancing competitive positioning [19] - **Strategic Acquisitions**: Acquired a BCMA TCE to expand the reach in autoimmune diseases, allowing for a broader patient base [27][28] Future Plans - **Pivotal Studies**: Plans to initiate a phase 2 single-arm study for CLN-049 in 2027, targeting relapsed refractory AML patients [40] - **Combination Studies**: Intent to begin a phase 1b/2 combination study with AZA in previously untreated AML patients [37] Zipalertinib Program - **NDA Submission**: Completion of the relapsed study marks a significant milestone, with Taiho leading further development [41] - **Financial Impact**: Potential for $130 million in regulatory milestones and a 50/50 profit share in the U.S. [42] Conclusion - **Outlook for 2026**: A defining year for Cullinan Therapeutics with multiple catalysts and significant potential in both autoimmune diseases and oncology, supported by a strong financial position and strategic development plans [9][43]

Financial Data and Key Metrics Changes - The company generated adjusted EPS of $1.99, a 47% improvement from the prior year [5] - GAAP earnings were $2.05 per diluted share, with adjusted earnings including one-time benefits of $28 million or $0.20 per diluted share [12] - Adjusted revenue in the title segment was $1.9 billion, up 14% compared to the same quarter of 2024 [13] - Personnel costs increased by 11% to $581 million, primarily due to incentive compensation [16] Business Line Data and Key Metrics Changes - Commercial revenue grew by 35% to $339 million, driven by higher average revenue per order and transaction volumes [13][14] - Closed orders increased by 10% year-over-year, while average revenue per order rose by 22% to a record $18,600 per closing [14] - Residential purchase revenue decreased by 4%, reflecting a 7% decline in closed orders [14] - Refinance revenue increased by 47%, driven by a 44% increase in closed orders [14] Market Data and Key Metrics Changes - Existing home sales are running at approximately 4 million units, below the normalized level of 5.5 million units [6] - Open purchase orders were down 7% in the fourth quarter, indicating continued weakness in purchase revenue [10] - Refinance open orders were up 72% in January, suggesting a positive trend for the first quarter [10] Company Strategy and Development Direction - The company aims to be the best title and escrow company in the industry, focusing on modern AI-powered products to improve customer experience and operational efficiency [11] - The launch of the Endpoint platform and the Sequoia title production engine are key strategic initiatives, with plans for national rollout over the next two years [8][36] - The company is also focused on enhancing its competitive advantage through data assets and adjacent businesses [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, expecting growth across major revenue drivers: commercial, purchase, and refinance [9] - The company anticipates a record revenue year for commercial, with a strong pipeline despite uncertainty [9] - Management noted that the rate lock-in effect is expected to fade, allowing for improved affordability in many markets [10] Other Important Information - The company ended the year with $94 million in 1031 exchange deposits, which have grown to over $300 million [9] - The effective tax rate for the quarter was 25.7%, higher than the normalized rate of 24% due to higher income from non-insurance businesses [20] Q&A Session Summary Question: Potential improvement in commercial revenue for 2026 - Management is optimistic about commercial revenue growth in 2026, citing strong momentum and a robust pipeline, but specific growth percentages are uncertain [24] Question: Contribution from data centers to commercial premiums - Data centers accounted for roughly 10% of commercial premiums, with significant growth expected [25][26] Question: Impact of Sequoia and Endpoint on margins - Management indicated that margin drag from legacy platforms will gradually alleviate as investments in modern platforms increase [34] Question: Drivers of adjusted pretax margin expansion - The higher margin is attributed to commercial tailwinds, effective expense management, and a favorable revenue mix [50] Question: Texas title insurance rate reduction impact - The rate change is expected to lower total revenue and net operating revenue in the title segment by about 50 basis points [86]

Software’s DeepSeek AI moment, Dow 50k, a yo-yo dollar, and “sell America” are market narrativesPrice action, corporate profits, and perhaps even jobs data buck bearish viewpointsInvestor conferences through quarter-end offer color on macro risks and opportunitiesIs artificial intelligence (AI) eating the software world? That might be the industry-specific question investors, analysts, and executives will toss around in the months ahead.The first week of February was the China DeepSeek AI moment for softw ...

Sen. Thom Tillis, R-N.C., on Thursday rejected a proposal aimed at ending the Department of Justice's controversial criminal probe into Federal Reserve Chair Jerome Powell and clearing a path for his successor, Kevin Warsh, to be confirmed.The proposed off-ramp, which has been floated by at least one Republican lawmaker this week, would see the Powell investigation handed off from the DOJ to the Senate Banking Committee. The idea is an attempt to thread a political needle: It would drop the threat of crimin ...

The new U.S.–India trade deal won't trigger an immediate supply-chain overhaul, but it will "tilt the spreadsheet" for U.S. multinationals weighing China alternatives, one strategist said.The closely watched agreement, announced by President Donald Trump earlier this month, marks a significant shift in a key bilateral relationship. As one of America's most important trading partners, India is poised to play a larger role in U.S. supply chains, with implications extending beyond tariffs.Divakar Vijayasarathy ...

Mark Gitin: Thanks, Eugene, and good morning, everybody. Fourth quarter revenue came in above our expectations, increasing 17% year over year and 9% sequentially. Revenue growth was driven by further stabilization in industrial demand, new opportunities, and a disciplined focus on our growth initiatives. This focus led to strong results in medical and advanced applications this quarter. Materials processing revenue was up 6% sequentially and 17% year over year, driven by stable general industrial demand and ...

For the quarter ended December 2025, Lincoln Electric Holdings (LECO) reported revenue of $1.08 billion, up 5.6% over the same period last year. EPS came in at $2.65, compared to $2.57 in the year-ago quarter.The reported revenue represents a surprise of -0.94% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $2.53, the EPS surprise was +4.67%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

Melco Resorts (MLCO) reported $1.29 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 8.6%. EPS of $0.14 for the same period compares to -$0.01 a year ago.The reported revenue represents a surprise of -1.2% over the Zacks Consensus Estimate of $1.31 billion. With the consensus EPS estimate being $0.12, the EPS surprise was +21.74%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Core Viewpoint - Rigetti Computing is focused on developing quantum computing technology but faces significant competition and challenges, leading to a downgrade in its stock rating and concerns about its financial performance [2][6]. Group 1: Company Overview - Rigetti Computing (NASDAQ:RGTI) aims to revolutionize computing through quantum mechanics, targeting faster problem-solving capabilities compared to traditional computers [1]. - The company is currently trading at $16.46, with a market capitalization of approximately $5.43 billion [5]. Group 2: Financial Performance - Rigetti's shares have declined by 23% year-to-date, attributed to a reset in the company's roadmap and disappointing financial results [2][6]. - The company is experiencing declining revenue, compressed gross margins, and ongoing operating losses [4]. Group 3: Product Development and Contracts - The launch of Rigetti's 108-qubit Cepheus system has been delayed to early 2026, raising investor concerns [3]. - Despite setbacks, Rigetti has secured $8.4 million in contracts with India's C-DAC and the U.S. Air Force, providing some medium-term visibility [3][4]. - The company plans to achieve over 150 qubits by 2026 and exceed 1,000 qubits by 2027 [3]. Group 4: Market Sentiment - Cowen & Co. downgraded Rigetti to a "Hold" rating amid the stock's decline and concerns over its financial outlook [2][6]. - The stock has fluctuated between a low of $15.75 and a high of $17.09 in recent trading [5].